SYNDAX PHARMACEUTICALS INC (SNDX) Forecast, Price Target & Analyst Ratings
NASDAQ:SNDX • US87164F1057
22.07 USD
+0.49 (+2.27%)
At close: Mar 6, 2026
22.37 USD
+0.3 (+1.36%)
After Hours: 3/6/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SYNDAX PHARMACEUTICALS INC (SNDX).
Forecast Snapshot
Consensus Price Target
$40.17
+ 82.02% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.56
Revenue Estimate71.734M
ChartMill Buy Consensus
87.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$40.17
Upside
+ 82.02%
From current price of $22.07 to mean target of $40.17, Based on 20 analyst forecasts
Low
$27.27
Median
$38.76
High
$58.80
Price Target Revisions
1 Month
0.20%
3 Months
2.81%
Price Target Summary
20 analysts have analysed SNDX and the average price target is 40.17 USD. This implies a price increase of 82.02% is expected in the next year compared to the current price of 22.07.
The average price target has been revised upward by 2.81% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.00%
SNDX was analyzed by 20 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about SNDX.
In the previous month the buy percentage consensus was at a similar level.
SNDX was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-27 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-09 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-24 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-04 | UBS | Maintains | Buy -> Buy |
| 2025-11-04 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-27 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-19 | BTIG | Reiterate | Buy -> Buy |
| 2025-09-10 | Stifel | Reiterate | Buy |
| 2025-09-05 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-09-04 | Guggenheim | Initiate | Buy |
| 2025-08-05 | BTIG | Maintains | Buy -> Buy |
| 2025-08-05 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-15 | UBS | Maintains | Buy -> Buy |
| 2025-07-10 | Goldman Sachs | Initiate | Buy |
| 2025-05-06 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-05-06 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2025-03-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-04 | Citigroup | Maintains | Buy -> Buy |
| 2025-03-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-08 | ScotiaBank | Maintains | Sector Perform -> Sector Perform |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.56
Revenue Estimate71.734M
Revenue Q2Q257.92%
EPS Q2Q43.29%
Number of Analysts11
Next Earnings Revisions
Revenue (1 Month)
0.96%
Revenue (3 Months)
-0.21%
EPS (1 Month)
1.32%
EPS (3 Months)
-0.82%
Next Earnings Summary
SNDX is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.56 USD and the consensus revenue estimate is 71.73M USD.
The next earnings revenue estimate has been revised downward by 0.21% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 23.68M | 172.352M 627.84% | 365.47M 112.05% | 552.75M 51.24% | 681.29M 23.25% | 931.31M 36.70% | 1.111B 19.29% | 1.386B 24.75% | 1.591B 14.79% | 1.291B -18.86% | ||
| EBITDA YoY % growth | -229.942M -51.51% | -339.664M -47.72% | -273.078M 19.60% | -143.119M 47.59% | -35.018M 75.53% | 123.7M 453.25% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -229.954M -51.48% | -339.672M -47.71% | -273.084M 19.60% | -128.34M 53.00% | -20.609M 83.94% | 154.81M 851.17% | 316.12M 104.20% | 461.08M 45.86% | 779.64M 69.09% | 992.87M 27.35% | 564.77M -43.12% | |
| Operating Margin | N/A | -1,434.43% | -158.45% | -35.12% | -3.73% | 22.72% | 33.94% | 41.50% | 56.25% | 62.41% | 43.75% | |
| EPS YoY % growth | -2.96 -20.82% | -3.73 -26.01% | -3.29 11.80% | -1.58 52.05% | -0.22 85.92% | 1.02 558.19% | 2.47 142.35% | 3.48 40.94% | 5.25 51.12% | 6.55 24.72% | 4.62 -29.48% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.56 43.29% | -0.46 44.15% | -0.37 47.32% | -0.25 68.09% |
| Revenue Q2Q % growth | 71.734M 257.92% | 82.972M 118.59% | 96.249M 109.83% | 115.64M 68.26% |
| EBITDA Q2Q % growth | -47.076M 43.63% | -40.859M 41.09% | -39.693M 30.88% | N/A |
| EBIT Q2Q % growth | -45.14M 45.95% | -35.308M 49.09% | -24.094M 58.04% | -10.863M 82.63% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
32.18%
EPS Next 5 Year
25.04%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
58.71%
Revenue Next 5 Year
45.49%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
35.00%
EBIT Next 5 Year
N/A
SYNDAX PHARMACEUTICALS INC / SNDX Forecast FAQ
What is the price target for SNDX stock?
20 analysts have analysed SNDX and the average price target is 40.17 USD. This implies a price increase of 82.02% is expected in the next year compared to the current price of 22.07.
What is the next earnings date for SNDX stock?
SYNDAX PHARMACEUTICALS INC (SNDX) will report earnings on 2026-05-04.
Can you provide the consensus estimates for SYNDAX PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of SYNDAX PHARMACEUTICALS INC (SNDX) is -0.56 USD and the consensus revenue estimate is 71.73M USD.
What is the expected long term growth rate for SNDX stock?
The expected long term growth rate for SYNDAX PHARMACEUTICALS INC (SNDX) is 58.71%.